To conclude, the methods presented here open up the possibility of systematic study of gene deletions promoting PD-1 or PD-L1 ICB resistance in murine tumor models, facilitating the discovery of alternative treatment options and a deeper understanding of the immune consequences of tumor mutations, with potential clinical implications. Here, PDCD1 is linked to neoplasm.